tbuckley/cabot-search huggingface dataset:
Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.
Authors: T Coyle, J Baptista, J Winfield, K Clark, B Poiesz, J Kirshner, A Scalzo, N Newman-Palmer, R King, S Graziano
Journal: Journal of Clinical Oncology (1990)

We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma. There were 31 patients entered and 27 patients assessable for response. The median age was 49 years old. All patients had prior maximal radiotherapy, and eight had previous chemotherapy. Responses were determined based on clinical and computed tomographic (CT) scan/magnetic resonance imaging (MRI) criteria. The response rate (partial response [PR] plus objective qualitative response [OQR] plus complete response [CR]) was 52% with one CR. The response rate was higher in patients with anaplastic astrocytoma as compared with glioblastoma multiforme (P less than .05). The median duration of response was 42 weeks. Median survival for all assessable patients was 30 weeks, and for responders, it was 60 weeks. Response was correlated with ability to decrease dexamethasone doses and improved performance status. Toxicity was mainly hematologic with leukopenia being common. There was one treatment-related death from listeria meningitis, and two patients developed Pneumocystis carinii pneumonia. There were three episodes of neutropenic fever. We conclude that MOP is active and merits further investigation in adult high-grade glioma.
Multiple Injuries to the Left Lower Extremity
Authors: Otto E. Aufranc
Journal: JAMA (1963)

Dr. J. Gavin Manson:A 41-year-old widow was admitted to the Massachusetts General Hospital from another hospital eight days after having been severely injured in an automobile accident. She had not lost consciousness, but she had been in shock when she arrived at the other hospital. The emergency treatment necessary to bring her out of shock had required two units of dextran and two units of whole blood.  Assessment of her injuries at that time had revealed multiple cuts, bruises, and abrasions, an open fracture of the left patella, a fracture of the left hip, multiple rib fractures, with a short flail segment of the left chest anteriorly, a fracture of the left os calcis, and a trimalleolar fracture of the left ankle. She had received 3,000 units of tetanus antitoxin. A Foley catheter had been inserted into the bladder and she had required intravenous feedings because of persistent ileus.
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Authors: Tetyana Pertseva, Kateryna Gashynova
Journal: European Respiratory Journal (2014)

Aim:  To evaluate response to inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination in COPD pts with different SPD level.   Study population:  18 steroid-naive pts with stable COPD.   Methods:  At baseline combination of Fluticasone propionate 500 mcg + Salmeterol 50 mcg (Seretide Discus, GlaxoSmithKlein) BID were prescribed to all pts.  Exacerbation history during past year, Spirometry (by Masterlab, Viasis), and plasma SPD (by ELISA, HycultBiotech) were evaluated in all pts at baseline and 1 year after starting of therapy.   Results:  In accordance with baseline plasma SPD all pts were divided on two groups: Group I (n=8) with SPD  l  600 mg/dl; Group II (n=10) with SPD  g 600 mg/dl. Both groups were similar regarding to age, sex, smoking status and pulmonary function. Exacerbation rate was significantly higher in Group II (2.35±0.37) vs. Group I (1.03±0.21), p=0.003.  After 1 year therapy tendency to the improvement of FEV1 was observed in both groups, but the difference with baseline was not significant (p g 0.05). At the same time, unlike Group I, pts of Group II demonstrate significant declining in plasma SPD from 1183.354 (683.700-1506.230) ng/ml at baseline to 735.460 (85.790-1250.34) ng/ml (p = 0.025) after 1 year of therapy. Exacerbation rate decreased from baseline in both groups (p l 0.05), but in Group II this changes were significantly greater than in Group I.   Conclusions:  1. Treatment with ICS+LABA combination in COPD pts with high level of plasma SPD leads to the great improving in exacerbation rate and significant plasma SPD declining.  2. High plasma SPD could be considered as an additional criterion for ICS+LABA prescription in pts with COPD.
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes
Authors: Joshua T. Schiffer, David A. Swan, Amalia Magaret, Lawrence Corey, Anna Wald, Joachim Ossig, Helga Ruebsamen-Schaeff, Susanne Stoelben, Burkhard Timmler, Holger Zimmermann, Murad R. Melhem, Scott A. Van Wart, Christopher M. Rubino, Alexander Birkmann
Journal: Science Translational Medicine (2016)

A mathematical model for antiviral clinical trials improves dose selection and understanding of drug-virus interaction.
Commentary on “Doping prevalence among preadolescent athletes: a 4-year follow-upDoping prevalence among preadolescent athletes: a 4-year follow-up”
Authors: Gerhard Treutlein
Journal: British Journal of Sports Medicine (2007)

Everybody knows that drug abuse and abuse of medicaments is a growing problem, not only for sportsmen but for many young people and their health in our societies. The author has …
Protection Against 7,12-Dimethylbenz[a]anthracene-lnduced Rat Mammary Carcinoma by Infection With Mouse Xenotropic Type C Virus2
Authors: Owen S. Weislow, Patton T. Allen, Roger E. Shepherd, Daniel R. Twardzik, Arnold K. Fowler, Alfred Hellman
Journal: JNCI Journal of the National Cancer Institute (1978)

A single ip inoculation of female, outbred Sprague-Dawley rats with a viable mouse xenotropic type C virus significantly reduced the incidence and/or retarded the development of mammary carcinoma induced by 7, 12-dimethylbenz[a]anthracene administered orally 7 days after virus. Although infectious virus could not be isolated from organs of infected rats, high titers of circulating and tumor-associated antibodies were detected against the viral internal core protein p30, and a low-grade antibody response to intact virus or envelope glycoprotein was found. Moreover, a cell-mediated immune response, measured by lymphocyte transformation, was detected with the use of intact virus but not with p30 antigen. No immunity developed after a single inoculation of UV-inactivated virus. These data indicated that inoculation of adult individuals of heterologous species with viable xenotropic mouse type C virus resulted in the rapid disappearance of infectious virus from the recipient, followed by the development of both humoral and cellular immunity to virion constituents. These events led, by unknown mechanisms, to the effective retardation of chemical carcinogenesis when infection preceded carcinogen administration.
Alterations in cell proliferation and apoptosis in human colon cancers with microsatellite instability
Authors: F. A. Sinicrope, M. Garrity, R. L. Rego, A. J. French, N. R. Foster, D. J. Sargent, R. M. Goldberg, J. A. Laurie, L. J. Burgart, S. N. Thibodeau, T. E. Witzig
Journal: Journal of Clinical Oncology (2006)

10022 Background: Patients with colon cancers displaying high frequency microsatellite instability (MSI-H) are reported to have a favorable prognosis compared to microsatellite stable (MSS) tumors. However, prognostic factors underlying this observation are poorly understood. We studied apoptotic and proliferative indices and their relationship to MSI status, clinicopathological features, and patient survival rates. Methods: Archival Dukes’ stage B2 (n=83) and C (n=246) primary colon adenocarcinomas from patients enrolled in five 5-fluorouracil-based adjuvant therapy trials were analyzed for MSI using a PCR-based assay (MSI-H: ≥30% of loci with instability), and expression of hMLH1, hMSH2 and p53 proteins by immunostaining. Apoptosis was analyzed by the TUNEL assay and the proliferative index (PI: S phase + G 2 M) and DNA ploidy by flow cytometry. Correlations between markers and associations with overall survival (OS) censored at 8 yrs were sought. Results: MSI-H (n=58.18%) tumors were more likely proximal, diploid, high grade, p53 negative (vs. MSS/MSI-L; all p&lt;0.0001), and from women (p=0.002). Of 58 MSH-H cases tested, 54 showed loss of hMLH1 (n=50) or hMSH2 (n=4) proteins. Median proliferative index (PI) [12.6 vs. 17.4; p=0.0002] was reduced in MSI-H versus MSS/MSI-L tumors. Lower PI was associated with diploidy (p&lt;0.0001) and negative p53 expression (p=0.003). Apoptotic indices (AIs) were increased in MSI-H cancers (vs. MSS/MSI-L, p=0.082), as was the AI/PI ratio (p=0.0065). Interestingly, AI (p=0.02) and AI/PI (p&lt;0.0001) were significantly increased in diploid versus nondiploid tumors, and after removal of MSI-H cases, relationships held for PI and AI/PI with ploidy. Better OS was related to MSI-H (p=0.032), loss of hMLH1 or hMSH2 (p=0.024), diploidy (p=0.0015), and lower PI (p=0.078), but not AI, AI/PI, nor p53 (adjusting for stage, grade, treatment and stratifying by study). Conclusions: MSI-H tumors are characterized by reduced proliferative indices and a higher ratio of apoptosis to proliferation, reflecting slower tumor growth rates compared to MSS/MSI-L tumors. These features may contribute to their better survival. Lower PI and increased AI/PI are also features of diploid MSS cancers. [Table: see text]
The Role of Clozapine in Treatment-Resistant Schizophrenia
Authors: John M. Kane, Christoph U. Correll
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Phase II trials of small-cell lung cancer.
Authors: E L Korn, R Simon, M A Friedman, T D Moore
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.8.1369 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1321895 Phase II trials of small-cell lung cancer. E L KornxE L KornSearch for articles by this author , R SimonxR SimonSearch for articles by this author , M A FriedmanxM A FriedmanSearch for articles by this author , T D MoorexT D MooreSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.8.1369 PDF "Phase II trials of small-cell lung cancer.." Journal of Clinical Oncology, 10(8), pp. 1369–1370© 1992 by American Society of Clinical Oncology
A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer
Authors: A. Forero-Torres, J. Galleshaw, C. Jones, I. Percent, L. Nabell, J. Carpenter, C. Falkson, H. Krontiras, K. Bland, J. De Los Santos, M. N. Saleh
Journal: Journal of Clinical Oncology (2008)

625 Background: Preclinical studies suggest that up-regulation of tumor cell VEGF is a mechanism to subvert estrogen dependence in hormone responsive breast cancer resulting in reduced efficacy or acquired resistance; we hypothesized that the combination of bevacizumab (an anti-VEGF MoAb) and hormone therapy would be more effective than hormone therapy alone for the treatment of breast cancer. Methods: Postmenopausal, ER and/or PR positive and Her-2-neu negative, operable (T2–4a-c/N 0–2/M0) breast cancer patients were enrolled. Patients received letrozole (2.5 mg po daily) and bevacizumab (15 mg/kg IV q 3 wks). Patients were evaluated every 6 wks; patients with CR/PR/SD in the first evaluation continued; after an additional 6 weeks of therapy patients with PD or SD were taken off-study and those patients with PR/CR completed 24 weeks of therapy. Definitive surgery was performed no sooner than 4 wks after the last dose of bevacizumab. Patients continued letrozole while waiting for surgery. 26 patients were enrolled with 1 patient too early to evaluate (Dec 2007). Results: The 25 patients that completed the study had a median age of 63 years (range; 54 to 79) and an ECOG score of 0 for all patients. 20 patients were stage II and 6 patients stage III. No treatment-related severe adverse events were seen. Treatment-related toxicities were as follows: 2 patients were taken off-study because of uncontrolled hypertension occurring on initial infusion of bevacizumab, grade 3 hypertension (n=5), grade 2 hypertension (n=7), grade 2 fatigue (n=4), grade 2 joint pain (n=3), grade 2 hot flashes (n=2), grade 1 proteinuria (n=1). Of the 22 patients evaluable for response, 4 patients had pCR in the breast (18%) and 3 of them had negative lymph nodes, 6 patients had a PR greater than 80% (28%), 6 patients had a PR between 20–80% (28%) and 2 patients had PD (at 9 weeks and 16 weeks). Overall response (CRs and PRs) 74%. There have been no problems with wound healing or bleeding related to surgery or progressive disease while awaiting surgery. Conclusions: Combination of letrozole and bevacizumab has substantial clinical efficacy and is well tolerated. The combination therapy will be evaluated in a randomized Breast Cancer Research Consortium Trial. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
Authors: M. Colleoni, N. Rotmensz, S. Andrighetto, P. Maisonneuve, A. Sonzogni, G. Pruneri, C. Casadio, A. Goldhirsch, G. Viale
Journal: Journal of Clinical Oncology (2007)

10586 Background: Peritumoral vascular invasion (PVI) has been recently recognized as a significant prognostic indicator for women with operable breast cancer, yet the clinical relevance of the degree of PVI in patients with no or limited involvement of the axillary nodes is unknown. Methods: 2606 consecutive patients with pT1–3, pN0 (1586)-1a (1020), and M0, operated and counseled for medical therapy from 1/2000 to 12/2002 were prospectively classified according to the degree of PVI: absent (2017, 77.4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%). The median follow-up was 3.8 years for disease-free survival (DFS) and 4.3 years for overall survival (OS). Results: Patients with extensive PVI were more likely be younger, to have larger tumors, high tumor grade, axillary positive nodes, high Ki-67 expression, and HER2/neu over-expression if compared with patients having less amount if PVI (p for trend, &lt;.0001). Patients with diffuse PVI were prescribed significantly more frequently anthracycline containing chemotherapy and less endocrine therapy alone (p for trend, &lt;.0001). In patients with node negative disease a statistically significant difference in DFS, risk of distant metastases and OS was observed at the multivariate analysis for diffuse PVI versus no PVI (Hazard Ratios: 2.11, 95% CI, 1.02 to 4.34, P&lt;.0001 for DFS; 4.51, 95% CI, 1.96 to 10.4, P&lt;.0001 for distant metastases; 3.55, 95% CI, 1.24 to 10.1, P=.02 for OS). Conclusions: Extensive peritumoral vascular invasion has a prognostic role in patients with axillary lymph node negative breast cancer. The extent of vascular invasion should be considered in the therapeutic algorithm in order to proper select targeted adjuvant treatment. No significant financial relationships to disclose.
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin for locally advanced head and neck cancer: A preliminary result
Authors: J. G. Kim, J. H. Baek, S. K. Sohn, D. H. Kim, S. B. Jeon, J. S. Park, J. H. Sohn, J. C. Kim, I. K. Park, K. U. Park
Journal: Journal of Clinical Oncology (2005)

5587 Background: The objectives of the present study were to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin for locally advanced head and neck cancer. Methods: Thirty-one previously untreated patients with stage III or IV squamous cell carcinoma of head and neck were enrolled into the study. Chemotherapy consisted of two cycles of intravenous cisplatin of 80 mg/m2 on day 1 and oral capecitabine 825 mg/m2 twice daily from day 1 to 14 in a 3-week interval. Radiation was delivered in a standard format at 1.8 Gy/d to a total dose of 70.2 to 72 Gy. Results: The median age of patients was 63.0 years (range, 35–75 years), and 27 (87.1%) patients were male. Primary sites of tumors were as follows: oral cavity (n=5), oropharynx (n=9), hypopharynx (n=7), larynx (n=1), nasopharynx (n=6), and paranasal sinus (n=3). Thirty (96.8%) out of 31 patients completed the planned treatment. After chemoradiotherapy, 24 complete responses (CR; 77.4%) and 4 partial responses (PR; 12.9%) were confirmed, giving an overall response rate of 90.3%. Grade 3 or 4 neutropenia occurred in only 2 patients (6.5%), and grade 3 febrile neutropenia was observed in 1 patients (3.2%). There was no treatment-related death. The common non-hematological toxicities were mucositis (grade 3/4, 45.2%) and nausea (grade 3/4, 29.0%). At a median follow-up duration of 215 days (range, 93–388 days), median survival has not yet been reached, while the estimated overall survival and progression free survival at 1-year was 83.1 ± 10.6% and 59.0 ± 15.4%, respectively. Conclusions: Concurrent chemoradiotherapy with capecitabine and cisplatin was found to be well-tolerated and effective in patients with locally advanced head and neck cancer. Long-term follow-up is warranted to evaluate the late treatment failure and complications. No significant financial relationships to disclose.
Blood Polymorphonuclear Leukocytes From the Majority of Sickle Cell Patients in the Crisis Phase of the Disease Show Enhanced Adhesion to Vascular Endothelium and Increased Expression of CD64
Authors: Emma Fadlon, Susanne Vordermeier, Thomas C. Pearson, Anthony R. Mire-Sluis, Dudley C. Dumonde, Julia Phillips, Keith Fishlock, K. Alun Brown
Journal: Blood (1998)
IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy
Authors: Sebastian M. Lechner, Lilia Abbad, Erwan Boedec, Christina Papista, Marie-Bénédicte Le Stang, Christelle Moal, Julien Maillard, Agnès Jamin, Julie Bex-Coudrat, Yong Wang, Aiqun Li, Paolo G.V. Martini, Renato C. Monteiro, Laureline Berthelot
Journal: Journal of the American Society of Nephrology (2016)

IgA nephropathy (IgAN), characterized by mesangial IgA1 deposits, is a leading cause of renal failure worldwide. IgAN pathogenesis involves circulating hypogalactosylated IgA1 complexed with soluble IgA Fc receptor I (sCD89) and/or anti-hypogalactosylated-IgA1 autoantibodies, but no specific treatment is available for IgAN. The absence of IgA1 and CD89 homologs in the mouse has precluded in vivo proof-of-concept studies of specific therapies targeting IgA1. However, the α1KI‑CD89Tg mouse model of IgAN, which expresses human IgA1 and human CD89, allows in vivo testing of recombinant IgA1 protease (IgA1‑P), a bacterial protein that selectively cleaves human IgA1. Mice injected with IgA1‑P (1-10 mg/kg) had Fc fragments of IgA1 in both serum and urine, associated with a decrease in IgA1-sCD89 complexes. Levels of mesangial IgA1 deposits and the binding partners of these deposits (sCD89, transferrin receptor, and transglutaminase 2) decreased markedly 1 week after treatment, as did the levels of C3 deposition, CD11b(+) infiltrating cells, and fibronectin. Antiprotease antibodies did not significantly alter IgA1‑P activity. Moreover, hematuria consistently decreased after treatment. In conclusion, IgA1‑P strongly diminishes human IgA1 mesangial deposits and reduces inflammation, fibrosis, and hematuria in a mouse IgAN model, and therefore may be a plausible treatment for patients with IgAN.
A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8)
Authors: D. A. Rinaldi, N. A. Lormand, J. M. Rainey, J. E. Brierre, J. L. Cole, K. B. Roden
Journal: Journal of Clinical Oncology (2004)

2090 Background: GEM and DOC have demonstrated single-agent antitumor activity against a variety of malignancies. Pharmacological studies of GEM have demonstrated that the intracellular concentration of its active triphosphate metabolite is maximized at a dose rate of approximately 10 mg/m2/minute. The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), and toxicity profile for GEM and DOC when administered to patients with advanced solid tumors on a weekly schedule. Methods: Both GEM and DOC were administered on days 1 and 8 of each 21-day course, with GEM administered at a rate of 10 mg/m2/minute and DOC over 60 minutes (after GEM). The initial dose levels were 600 mg/m2 and 25 mg/m2 for GEM and DOC, respectively. Results: Eight patients (5 men, 3 women, median age 60 years old) with advanced solid tumors have been treated with 25+ courses at 2 dose levels. Three patients were treated at dose-level 1 without DLT. Five patients have now been treated at dose level 2 (GEM 800 mg/m2 and DOC 25 mg/m2), with 1 too early to evaluate. One patient developed DLT (grade IV neutropenia with fever) and 2 patients experienced grade III thrombocytopenia. No grade III-IV non-hematologic side effects have been observed. No major responses have been observed as of yet, but 3 patients had dissease stabilization for at least 4 courses of treatment. Conclusions: The MTD of GEM and DOC on the current weekly schedule has not been established as of yet. Patient accrual is on-going at dose-level 2. Six patients will be treated at this level before dose-escalation if no further DLT is observed. Updated results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly
Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
Authors: J.F. Vansteenkiste, B. Cho, T. Vanakesa, T. De Pas, M. Zielinski, M.S. Kim, J. Jassem, M. Yoshimura, J. Dahabreh, H. Nakayama, L. Havel, H. Kondo, T. Mitsudomi, K. Zarogoulidis, O.A. Gladkov, B. Spiessens, V. Brichard, C. Debruyne, P. Therasse, N. Altorki
Journal: Annals of Oncology (2014)